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One of the enigmas in tumor biology is that different types of cancers are prevalent in different age groups. One
possible explanation is that the ability of a specific oncogene to cause tumorigenesis in a particular cell type depends
on epigenetic parameters such as the developmental context. To address this hypothesis, we have used the
tetracycline regulatory system to generate transgenic mice in which the expression of a c-MYC human transgene can be
conditionally regulated in murine hepatocytes. MYC’s ability to induce tumorigenesis was dependent upon
developmental context. In embryonic and neonatal mice, MYC overexpression in the liver induced marked cell
proliferation and immediate onset of neoplasia. In contrast, in adult mice MYC overexpression induced cell growth and
DNA replication without mitotic cell division, and mice succumbed to neoplasia only after a prolonged latency. In adult
hepatocytes, MYC activation failed to induce cell division, which was at least in part mediated through the activation of
p53. Surprisingly, apoptosis is not a barrier to MYC inducing tumorigenesis. The ability of oncogenes to induce
tumorigenesis may be generally restrained by developmentally specific mechanisms. Adult somatic cells have evolved
mechanisms to prevent individual oncogenes from initiating cellular growth, DNA replication, and mitotic cellular
division alone, thereby preventing any single genetic event from inducing tumorigenesis.
Citation: Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, et al. (2004) Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2(11): e332.
Introduction
The frequency of cancer development varies depending on
the age of the host. In humans, the most common childhood
cancers include tumors of the hematopoietic system, nervous
system, and skeletal muscle system. In contrast, in the adult
population, solid tumors of the lung, colon, breast, and
prostate are more common. Differences in types of cancers in
hosts of different ages may reﬂect the abundance of cells in a
differentiative state susceptible to tumorigenesis (Greaves
1986; Klein and Klein 1986). Indeed, many reports document
that oncogene activation generally induces tumorigenesis in
immature cellular lineages (Adams et al. 1985; Spanopoulou
et al. 1989; Pelengaris et al. 1999; Blyth et al. 2000).
We recently reported that upon oncogene inactivation
tumor cells can differentiate into mature cells, and in this
new differentiative context the reactivation of an oncogene
fails to restore tumorigenesis (Jain et al. 2002). Based on these
results, we speculate that only speciﬁc differentiative windows
provide the correct epigenetic program to permit oncogene
activation to initiate and sustain tumorigenesis. Here we
directly evaluate whether an oncogene’s ability to induce
tumorigenesis depends on the differentiative context when
this oncogene ﬁrst becomes activated. We have examined the
ability of the C-MYC oncogene to induce tumorigenesis in
mice of different ages using a novel conditional transgenic
model system for C-MYC–induced hepatocellular carcinoma
(HCC).
C-MYC (now referred to as MYC) is a member of a family of
proto-oncogenes comprising C-MYC, N-MYC, and L-MYC.
MYC encodes a transcription factor that, as part of a
heterodimeric complex with MAX, regulates the expression
of a multitude of genes involved in regulating cellular
proliferation and growth (Johnston et al. 1999; Grandori et
al. 2000; Oster et al. 2002; Pelengaris et al. 2002a). Over-
expression of MYC is commonly associated with tumori-
genesis. MYC exerts its neoplastic function by inducing
autonomous cellular proliferation and cellular growth, block-
ing differentiation, and inducing genomic destabilization
(Dang 1999; Felsher and Bishop 1999a; Grandori et al. 2000;
Oster et al. 2002; Pelengaris et al. 2002a; Karlsson et al. 2003).
It is generally assumed that MYC is restrained from causing
tumorigenesis because it concomitantly induces cellular
proliferation and apoptosis (Pelengaris et al. 2002a).
HCC is a common and generally incurable human
malignancy of epithelial cells (Thorgeirsson and Grisham
2002). HCC has been strongly associated with viral infections
such as hepatitis B and C; exposure to toxins, such as alcohol,
aﬂatoxin, and phenobarbital; and exposure to various
carcinogens such as polyvinyl chloride (Thorgeirsson and
Grisham 2002). Interestingly, the ability of these carcinogens,
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Open access, freely available online PLoS BIOLOGYsuch as the hepatitis viruses, to induce HCC depends on the
host age during infection. Hepatitis B infection acquired
during neonatal development versus adulthood results in a
several-magnitude increased risk of HCC (Chang et al. 1991).
These results suggest that there are differentiative windows
during liver development that may be more susceptible to
neoplastic transformation.
Human tumors have been analyzed extensively for genetic
events associated with HCC (Buetow et al. 1989; Tsuda et al.
1990; Boige et al. 1997; Piao et al. 1997). MYC oncogene
activation is one of the more common events in the
pathogenesis of HCC. MYC overexpression in human HCC
is most commonly associated with genomic ampliﬁcation
(Abou-Elella et al. 1996; Kawate et al. 1999). Human HCCs
exhibit ampliﬁcation of MYC in up to 50% of tumors (Abou-
Elella et al. 1996; Kawate et al. 1999). The presence of MYC
ampliﬁcation in HCC portends a more advanced and
aggressive clinical phenotype (Abou-Elella et al. 1996). Thus,
the MYC oncogene appears to play a critical role in the
pathogenesis of HCC.
The most compelling evidence that MYC is causally
associated with the etiology of HCC comes from animal
models (Sandgren et al. 1989; Fourel et al. 1990; Murakami et
al. 1993; Morgenbesser and DePinho 1994; Sargent et al. 1996,
1999; De Miglio et al. 1999; Santoni-Rugiu et al. 1999; Renard
et al. 2000). MYC is frequently activated through insertional
mutagenesis mediated by the hepadnavirus in woodchuck
liver tumors (Fourel et al. 1990; Renard et al. 2000).
Carcinogen-induced HCC in Wistar rats is associated with
MYC ampliﬁcation and overexpression (De Miglio et al. 1999).
The overexpression of MYC (as a transgene) and other
oncogenes (e.g., RAS, T antigen) in murine hepatocytes
results in HCC (Sandgren et al. 1989). The latency of HCC
in these transgenic mice is long, but is greatly accelerated by
the transgenic overexpression of transforming growth factor-
alpha (Murakami et al. 1993; Sargent et al. 1996, 1999;
Santoni-Rugiu et al. 1999). These results highlight that the
activation of MYC alone is not sufﬁcient to induce HCC.
Traditional transgenic systems that have been previously
used to study the role of oncogenes in tumorigenesis
continuously overexpress transgenes and hence preclude
the investigation of the initial and developmentally speciﬁc
consequences of oncogene activation. To investigate the
developmentally speciﬁc consequences of MYC overexpres-
sion in the pathogenesis of HCC in vivo, we used transgenic
mice in which the MYC proto-oncogene is conditionally
regulated via the tetracycline regulatory system (Tet system)
(Felsher and Bishop 1999b). We found that the ability of MYC
to induce cellular proliferation versus cellular growth, and
consequently its ability to induce tumorigenesis in murine
hepatocytes, was dependent on the age of the host. Our
results have implications for the mechanisms by which MYC
and other oncogenes initiate and are restrained from causing
tumorigenesis.
Results
A Conditional Model System for MYC-Induced HCC
We used the Tet system to conditionally express MYC in
murine hepatocytes (Kistner et al. 1996; Felsher and Bishop
1999b). We mated the transgenic line TRE-MYC (Felsher and
Bishop 1999b), which contains the tetracycline response
element adjacent to the human MYC cDNA, with the
transgenic line LAP-tTA (Kistner et al. 1996), which contains
a liver-speciﬁc enhancer that drives the expression of the
tetracycline-transactivating protein. Mice possessing both
transgenes exhibited increased expression of the MYC trans-
gene in their hepatocytes (Figure 1A). Mice possessing either
transgene alone did not overexpress MYC and lacked
evidence of morbidity or mortality. Similarly, mice possessing
both transgenes that were treated with doxycycline to
suppress MYC transgene expression did not exhibit a
Figure 1. MYC Overexpression in Adult Hepatocytes Results in HCC
(A) Western blot analysis demonstrating that mice transgenic for both
LAP-tTA and TRE-MYC conditionally express MYC protein in their
hepatocytes in the absence ( ) but not in the presence (þ)o f
doxycycline.
(B) Adult mouse with MYC-induced liver tumor.
(C) Histology of an adult MYC-induced liver tumor.
(D) Gross pathology of an adult liver tumor transplanted subcuta-
neously into a scid mouse.
(E) Histology of an adult tumor transplanted subcutaneously into a
scid mouse.
DOI: 10.1371/journal.pbio.0020332.g001
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enables us to conditionally regulate MYC expression in
murine hepatocytes.
To investigate if MYC overexpression is sufﬁcient to induce
HCC in our model system, we removed doxycycline treatment
in adult mice (6–12 weeks of age) transgenic for both TRE-
MYC and LAP-tTA. Ninety percent of adult mice over-
expressing MYC succumbed to liver tumors with a mean
latency of 35 weeks. At necropsy, mice exhibited marked
gross enlargement of the liver with multiple tumor masses
(Figure 1B). The normal liver architecture was disrupted by
nodular tumors with histological features typical of HCC.
Tumors were composed of dysplastic nests of cells with large
pleomorphic nuclei, delicate vesicular chromatin, and very
prominent nucleoli (Figure 1C). Tumors could invade into
the abdomen and the lung (Figure 2A–2C). These features
demonstrated that MYC overexpression in adult mice
resulted in HCC.
To conﬁrm that these tumors were malignant, we trans-
planted them subcutaneously into scid mice. Tumors formed
in the inoculated mice after an 8–10-week latency (see Figure
1D). The transplanted tumors displayed identical histology to
the primary transgenic tumor (see Figure 1E versus 1C).
Normal adult hepatocytes failed to induce tumors when
inoculated into scid mice. We conclude that MYC over-
expression in adult hepatocytes results in the formation of
highly malignant liver cancers with features consistent with
human HCC.
Developmental State of the Host Influences on Frequency
and Latency of Tumor Onset
To determine if the developmental state of host hepato-
cytes inﬂuenced the ability of MYC activation to induce
tumorigenesis, we induced MYC in cohorts of different ages
(Figure 3A). Mice that overexpressed MYC during embryonic
development of the liver succumbed to neoplasia within 10 d
of birth. Mice in which MYC was activated at birth (neonates)
succumbed to neoplasia within 8 weeks. Mice in which MYC
was induced at 4 weeks or 6–12 weeks of age developed
tumors after a mean latency of 15 and 35 weeks, respectively
(Figure 3A). We conclude that the ability of MYC activation to
induce tumorigenesis in hepatocytes is inversely correlated
with the developmental age of the host.
One possible explanation for our results was that the levels
of MYC induction were different in embryonic and neonatal
versus adult hosts. To address this possibility, we examined
total MYC protein levels by Western analysis using a
polyclonal antibody that recognizes both the human c-MYC
protein and the endogenous murine c-MYC (Figure 3B). In
neonatal and adult mice, MYC protein levels were induced at
similar levels (Figure 3B). In tumors from embryos, neonatal,
and adult mice, MYC protein levels increased an additional
5- to 10-fold over the levels observed in nontransgenic and in
MYC-induced nonneoplastic livers. Tumorigenic conversion
of hepatocytes was associated, in all age groups of mice, with
further increases in the levels of MYC protein (Figure 3B). We
obtained similar results by quantitative PCR analysis of
mRNA expression of the human MYC transgene (Figure 3C).
In neonatal and adult mice, MYC transgene expression was
induced at similar levels. In tumors from embryos, neonatal,
and adult mice, the levels of MYC transgene RNA increased
an additional 10-fold over the levels observed in nonmalig-
nant hepatocytes (Figure 3C). Hence, tumorigenic conversion
of hepatocytes was associated, in all age groups of mice, with
further increases in the levels of MYC transgene expression.
However, differences in the ability of MYC activation to
initiate tumorigenesis in mice of different ages did not
appear to be related to differences in the levels of induction
of MYC transgene expression. The increased levels of MYC
expression we observed in tumors likely reﬂect that the
proliferating tumor cells express more abundant levels of the
MYC transgene than normal hepatocytes. This observation is
consistent with observations described in other transgenic
models in which expression of transgenes is generally higher
in tumors than it is in the normal cellular counterparts (Weiss
et al. 2003).
MYC Activation in Embryonic and Neonatal Hepatocytes
Induces Cellular Proliferation and Tumorigenesis
To evaluate how MYC’s ability to induce tumorigenesis is
inﬂuenced by the age of mice, we investigated the initial
consequences of MYC activation in hepatocytes during
Figure 2. MYC-Induced Hepatic Tumors
Are Invasive and Metastatic
(A) Adult mouse with MYC-induced liver
tumor that has metastasized to the
abdomen and the lungs.
(B) Histology of an adult MYC-induced
lung metastasis.
(C) Histology of an adult MYC-induced
liver tumor.
(D) Gross pathology of a liver tumor
from a neonatal host transplanted sub-
cutaneously into a scid mouse.
DOI: 10.1371/journal.pbio.0020332.g002
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Developmental Context and Tumorigenesisdifferent developmental periods. Mice that overexpressed
MYC during embryonic development were born with livers
similar in weight and gross architecture to normal age-
matched livers, yet exhibited increasing numbers of neo-
plastic cells from birth thro u g ht h eﬁ r s tw e e ko fl i f e
associated with progressive abdominal enlargement. At
necropsy, abdominal enlargement was associated with
marked hepatomegaly with a 5-fold increase in total liver
weight (Figure 4A, and see Figure 8B below). Although these
livers were larger, the gross architecture was preserved
(Figure 4A, MYC ON versus MYC OFF). When we examined
the histology of the livers in which MYC was overexpressed
during embryogenesis, we found that they resembled liver
cancers (Figure 4B versus 4C) similar to the MYC-induced
HCCs we observed in adult mice (see Figure 1C versus 4C).
Hence, MYC overexpression appears to induce cellular
proliferation in neonatal hepatocytes that progresses rapidly
to neoplasia.
Figure 3. MYC’s Ability to Induce HCC Is
Inversely Correlated with the Age of the
Host at the Time of MYC Activation
(A) Survival of transgenic mice demon-
strates that tumorigenesis in the liver is
inversely correlated with the age of the
h o s ta tt h et i m eo fMYC induction.
Shown are cases where MYC was con-
stitutively expressed (&), newborn mice
in which MYC was activated at birth (~),
young mice in which MYC was activated
at 4 weeks of age (*), adult mice in
which MYC was activated at 6–12 weeks
of age (^), and transgenic mice treated
with doxycycline (&). Cohorts consisted
of 15–30 mice. Mice were scored when
moribund. MYC transgene expression
was induced to similar levels in the
differently aged cohorts of mice. Survival
time is measured as the time after MYC
induction.
(B) Western blot examining total MYC
protein levels (human MYC and endog-
enous murine c-MYC) in mice when MYC
is induced during embryonic develop-
ment, activated at birth, and activated
during adulthood (after 10 weeks of age).
Adult mice exhibited a progressive in-
crease in MYC protein levels during the
course of MYC induction, with a signiﬁcant increase in MYC protein in tumors. MYC protein levels in neonatal mice in which MYC was activated
at birth were slightly increased at 10 d of age, and signiﬁcantly increased at 18 d of age when these mice developed liver tumors. Liver tumors in
2- and 6-d-old neonatal mice that overexpressed MYC during embryonic development exhibited MYC protein levels similar to those observed in
neonatal and adult tumors.
(C) Real-time PCR analysis showing human MYC RNA levels in mice after different durations of MYC transgene induction. Adult livers exhibited
a small increase in MYC RNA levels upon MYC activation, and a much greater increase in MYC RNA in MYC-induced tumors (black bars). In
neonatal mice in which the MYC transgene was induced at birth, MYC RNA levels rose after 10 d of MYC activation. When these neonatal mice
developed liver tumors, they exhibited MYC RNA levels similar to those seen in adult tumors (gray bars). Mice in which MYC was overexpressed
during embryonic development developed liver tumors by 2 d of age and exhibited MYC RNA levels similar to those observed in neonatal and
adult tumors (white bars).
DOI: 10.1371/journal.pbio.0020332.g003
Figure 4. MYC Activation during Embry-
onic Development Induces a Rapid Onset
of Neoplasia
(A) A normal neonatal liver and a neo-
natal liver in which MYC was activated
embryonically.
(B) Histology of a normal neonatal liver
in which MYC was not activated.
(C) Histology of a neonatal liver in which
MYC was activated embryonically.
(D) DNA content of normal neonatal
hepatocytes.
(E) DNA content of neonatal hepatocytes
in which MYC was activated embryoni-
cally.
(F and H) Ki67 immunoﬂuorescence and
DAPI staining corresponding to a nor-
mal neonatal liver.
(G and I) Ki67 immunoﬂuorescence and
DAPI staining corresponding to a neo-
natal liver in which MYC was activated
embryonically.
DOI: 10.1371/journal.pbio.0020332.g004
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transit, we measured the DNA content of isolated nuclei from
normal hepatocytes and hepatocytes in which MYC was
activated during embryonic development (Figure 4D and 4E).
Normal neonatal hepatocytes mostly contained 2N DNA
content, consistent with most of the cells residing in G1
(Figure 4D). A minority of hepatocytes exhibited 4N and 2N–
4N DNA content, demonstrating that few cells were in G2/M
and S phase, respectively. In contrast, upon MYC activation
the proportion of neonatal hepatocytes with 2N–4N DNA
content substantially increased, suggesting that an increased
number of cells were in S phase (Figure 4E).
In order to conﬁrm that MYC activation caused tumori-
genesis by inducing cell proliferation, we performed Ki67
immunoﬂuorescence and DAPI staining in tumors induced
by MYC activation during embryonic development and in
age-matched nontransgenic livers. Indeed, there was evidence
for increased hepatocyte proliferation in the MYC-induced
neonatal tumor, as demonstrated by an increase in Ki67-
positive cells (Figure 4G and 4I versus 4F and 4H). We
conclude that MYC activation during embryonic develop-
ment causes neonatal hepatocytes to undergo DNA repli-
cation, cell cycle transit, proliferation, and almost immediate
neoplastic conversion.
To conﬁrm that MYC activation during embryonic devel-
opment induced tumorigenesis in neonatal livers, we trans-
planted neoplastic hepatocytes into scid mice. We found that
neoplastic neonatal hepatocytes readily formed tumors,
whereas the transplantation of normal neonatal hepatocytes
did not form tumors (see Figure 2D and unpublished data).
Therefore, MYC overexpression during embryonic develop-
ment of the murine liver causes hepatocellular tumorigenesis
within the ﬁrst 10 d of birth (Figure 3). We conclude that MYC
overexpression results in rapid neoplastic conversion of
neonatal hepatocytes.
Mice in which MYC was activated at birth exhibited
progressive abdominal enlargement during their second
and third weeks of life, and they showed signs of tumori-
genesis by 18 to 40 d of age. When these mice developed
tumors their livers were ten times the normal size, were paler,
exhibited a multitude of coalescing tumor nodules, and
preserved a normal gross architecture (unpublished data). We
did not observe any histological changes in the liver after 10 d
of MYC activation (Figure 5A versus 5B); however, by 18 d of
MYC activation the histology resembled liver cancers (Figure
5C versus 5D), similar to the MYC-induced HCCs we observed
in adults (Figure 5D versus 1C).
We performed Ki67 immunoﬂuorescence and DAPI stain-
ing in order to determine if MYC overexpression in neonatal
livers was inducing hepatocyte proliferation. At 10 d of age
the liver is in an active state of proliferation; thus, there was
little detectable difference in the number of Ki67-positive
cells between the MYC-activated and nontransgenic livers
(Figure 5E and 5I versus 5F and 5J). However, once these
livers became neoplastic, there was a great increase in the
number of Ki67-positive cells (Figure 5G and 5K versus 5H
and 5L).
MYC Activation in Adult Hepatocytes Induces Cellular
Growth, but Not Proliferation
We examined the initial consequences of MYC over-
expression in adult hepatocytes. In contrast to the rapid
neoplastic conversion we observed in embryonic or neonatal
hepatocytes (Figures 4 and 5), MYC overexpression in adult
hepatocytes caused a marked cellular growth, accompanied
by an even greater relative nuclear growth, as observed by
histological analysis (Figures 6–8). The effects of MYC
overexpression on the size of adult hepatocytes depended
on the duration of MYC activation. After 2 weeks of MYC
overexpression, no changes were observed in cell size
compared to normal hepatocytes (Figure 8C and unpublished
Figure 5. MYC Activation at Birth Induces
Proliferation of Neonatal Hepatocytes
(A) Histology of a normal 10-d-old neo-
natal liver.
(B) Histology of a 10-d-old liver in which
MYC was activated at birth.
(C) Histology of a normal 18-d-old neo-
natal liver.
(D) Histology of a MYC-induced neo-
natal liver tumor that developed after 18
d of MYC overexpression; MYC was
activated at birth.
(E–L) Ki67 immunoﬂuorescence (E–H)
and DAPI staining (I–L) of normal neo-
natal hepatocytes (E, G, I, and K), MYC-
activated hepatocytes (F and J), and
MYC-induced neonatal tumors (H and
L). Upon initial MYC activation in neo-
natal mice, there was a small increase in
Ki67-positive cells. MYC-induced neo-
natal tumors exhibited much higher
levels of Ki67-positive cells.
DOI: 10.1371/journal.pbio.0020332.g005
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Developmental Context and Tumorigenesisdata). However, after 4–8 weeks of MYC activation, adult
hepatocytes exhibited increased cell and nuclear size (Figure
6B versus 6A and Figure 8C). Similar results were observed in
over 20 different mice. Similarly, we observed that MYC
induces hypertrophy of hepatocytes by ﬂow cytometry
analysis (Figure 7). Further duration of MYC activation did
not induce further cell growth, as measured up to 50 weeks of
MYC activation (unpublished data). Thus, there may be an
absolute limit to the ability of MYC to induce liver growth.
MYC activation in adult hepatocytes was not associated with a
change in overall liver weight (Figure 8D). Since the cells
were bigger, but the overall weight of the liver did not
increase, we infer that the total number of hepatocytes was
unchanged or slightly decreased. One possible explanation
for these results is that MYC induced apoptosis, as described
below.
To examine if MYC activation induced proliferation of
adult hepatocytes, we measured Ki67 expression by immuno-
ﬂuorescence. We did not observe increased Ki67 expression
when MYC was overexpressed in the adult liver (Figure 6E
and 6H versus 6D and 6G). Only upon neoplastic conversion
of hepatocytes was there evidence for increased hepatocyte
proliferation (Figure 6F and 6I). We conclude that MYC
overexpression in adult hepatocytes induces increased
nuclear and cell growth, but not cell proliferation. Our
observations are consistent with previous reports that MYC
activation induces cell growth (Mateyak et al. 1997; Iritani and
Eisenman 1999; Johnston et al. 1999; Grandori et al. 2000;
Kim et al. 2000).
MYC activation in adult hepatocytes eventually culminated
in tumorigenesis, demonstrating that some adult hepatocytes
acquire the ability to undergo cell division. To conﬁrm this,
we measured the nuclear and cellular sizes in liver tumors.
When we examined the cell size in ten different tumors from
adult hosts, we found that in all tumors, the cell size was
reduced to below normal and the nuclear size was similar to
that of normal hepatocytes (Figures 6C and 8C). We were also
able to conﬁrm that the cell size of tumor cells was reduced to
below normal by FACS forward versus side scatter (unpub-
lished data). We conclude that MYC-induced malignant
conversion of adult hepatocytes is associated with the
acquired ability to undergo mitotic division.
Figure 6. MYC Activation in Adult Hepatocytes Induces Increased Cell
Size and Endoreduplication, and Only Results in Cell Proliferation upon
Neoplastic Conversion of Hepatocytes
(A) Histology of a normal liver.
(B) Histology of a liver 2 months after MYC activation.
(C) Histology of a MYC-induced liver tumor.
(D and G) Ki67 immunoﬂuorescence and DAPI staining of a normal
adult liver.
(E and H) Ki67 and DAPI staining of an adult liver after 8 weeks of
MYC activation.
(F and I) Ki67 and DAPI staining of a MYC-induced adult tumor.
(J) DNA content measured in normal hepatocytes.
(K) DNA content measured after MYC induction for 2 months.
(L) DNA content of a representative MYC-induced liver tumor.
DOI: 10.1371/journal.pbio.0020332.g006
Figure 7. MYC Activation in Adult Hepatocytes Induces Increased Cell
Size
A histogram obtained by FACS forward versus light scatter analysis of
adult hepatocytes from normal FVB/N livers (green), doxycycline-
treated transgenic livers (red), and livers in which the MYC transgene
was overexpressed for 3 months (blue). The x-axis represents cell size
and the y-axis represents cell count. Adult mice were matched for age.
DOI: 10.1371/journal.pbio.0020332.g007
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Endoreduplication
To further deﬁne the consequences of MYC activation on
the cell cycle, we examined the DNA content of isolated
nuclei from normal and MYC-activated adult hepatocytes. We
expected that if adult hepatocytes were restrained from
undergoing mitotic division, MYC activation might result in
endoreduplication. Age-matched normal hepatocytes ex-
hibited a 2N DNA content consistent with most of the cells
residing in G1, and there was no evidence for cells in S or G2/
M (Figure 6J). After MYC activation for 2 months, we found
that almost all nuclei had a 4N, 8N, or 12N DNA content,
suggesting that the cells replicated their DNA repeatedly
without dividing (Figure 6K). Almost no cells contained the
intermediate DNA content (2N–4N), demonstrating that very
few cells were in S phase at any given time. We conclude that
MYC activation induces endoreduplication of the genomes of
normal adult hepatocytes. Our results are consistent with
reports that MYC overexpression can enforce DNA repli-
cation, resulting in endoreduplication in normal cells (Cerni
et al. 1986; Mai et al. 1996; Chernova et al. 1998; Felsher et al.
2000).
We reasoned that if MYC was causing endoreduplication in
adult hepatocytes by arresting cell division and enforcing
DNA replication, then upon neoplastic conversion these
hepatocytes must acquire the ability to undergo mitotic
division and would no longer endoreduplicate. As predicted,
tumors did not exhibit evidence for endoreduplication
(Figure 6L). Greater than 70% of the tumor cells contained
a 2N–4N DNA content and none of the cells contained
greater than 4N DNA content. The majority of tumor cells
were in S phase (Figure 6L). Hence, MYC-induced tumori-
genesis in adult hepatocytes is associated with the acquired
ability to divide mitotically.
MYC Overexpression in Adult Hepatocytes Does Not
Induce Apoptosis
MYC-induced apoptosis is an important mechanism that
restrains MYC from causing tumorigenesis (Evan et al. 1992;
Pelengaris et al. 2000, 2002b). We reasoned that MYC may
induce cellular hypertrophy, but not an increase in liver mass,
because MYC induces apoptosis. Normal neonatal and adult
hepatocytes did not undergo apoptosis, as demonstrated by
TUNEL assay or DAPI staining (Figure 9A, 9B, 9E, and 9F).
Surprisingly, we could not ﬁnd evidence that MYC induced
apoptosis in adult hepatocytes by TUNEL assay or DAPI
staining after 2, 4, or 8 weeks of MYC induction prior to
tumor formation (Figure 9G and 9H and unpublished data).
Contrary to what we expected, MYC activation was only
associated with increased apoptosis in the hepatocytes of liver
cancers (Figure 9C, 9D, 9I, and 9J). Hence, apoptosis is not
necessarily the mechanism restraining MYC from causing
tumorigenesis, at least in hepatocytes (Pelengaris et al. 2002a).
However, we recognize that MYC could be inducing low levels
of apoptosis in hepatocytes, perhaps not easily detected by
TUNEL, since apoptotic cells may be rapidly eliminated from
the liver through the host reticulo-endothelial system. Such a
low level of apoptosis still could explain why in the adult liver
hepatocytes become hypertrophic but the liver mass does not
increase.
Loss of p53 Function Cooperates with MYC to Induce
Tumorigenesis in Adult Mice
Previously, we have shown that the loss of p53 function is
required to permit the cell division of normal mouse and
human ﬁbroblasts overexpressing MYC (Felsher et al. 2000).
We speculated that loss of p53 function might be similarly
required for MYC activation to induce cell proliferation and
tumorigenesis in hepatocytes. First, we examined if MYC
activation affected p53 protein expression. We found that
MYC activation was associated with an increase in p53 protein
levels in adult hepatocytes, as measured by Western analysis
(Figure 10A). Conversely, tumors in adult mice frequently
Figure 8. MYC Activation in Adult Hepatocytes Causes Cellular Hyper-
trophy
(A) Relative volumes of neonatal hepatocytes and nuclei after MYC
activation. Data are expressed as normalized volume plus or minus
the standard error of the mean. The volume was normalized by
dividing each measurement by the mean volume of normal 1-d-old
neonatal mice. Three livers were measured per time point. T, tumor.
(B) Neonatal liver weights of normal and MYC-activated livers. Three
to ﬁve livers were weighed per time point. Data are expressed as the
mean weight (grams) plus or minus the standard error of the mean.
(C) Relative volumes of adult hepatocytes and nuclei after MYC
activation. Volumes of cells are expressed as the mean volume divided
by the mean volume of hepatocytes from normal mice plus or minus
the standard error of the mean. Cells from two to three livers were
measured per time point.
(D) Adult liver weights after MYC activation. A total of nine livers
were measured per time point after MYC activation. Data are
expressed as the mean weight (grams) plus or minus the standard
error of the mean.
DOI: 10.1371/journal.pbio.0020332.g008
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10A and unpublished data). Not all tumors exhibited reduced
p53 expression. Since p53 mediates its function largely
through inducing the transcription of many different genes,
we evaluated if tumors exhibited a loss of p53 function by
measuring the expression of these target genes. We found by
Northern analysis that the p53 target genes, p21 and MDM2,
were induced upon MYC activation in adult livers (Figure
10C). Conversely, MYC-induced adult HCCs frequently
exhibited reduced or no expression of p53 downstream
Figure 9. MYC Activation Does Not Induce
Apoptosis in Murine Hepatocytes
TUNEL assay (A, C, E, G, and I) and DAPI
staining (B, D, F, H, and J) of normal (A,
B, E, and F) and MYC-activated (C, D, and
G–J) hepatocytes of neonatal (A–D) and
adult (E–J) mice. After 4 weeks of MYC
activation in adult hepatocytes, there
was no evidence of apoptosis either by
TUNEL assay (G) or by DAPI staining of
nuclei (H). MYC activation is associated
with increased apoptosis with the neo-
plastic conversion of neonatal (C) and
adult (I) hepatocytes. Representative
data from one of three experiments are
shown. Identical results were seen when
MYC was activated for 2 or 8 weeks.
DOI: 10.1371/journal.pbio.0020332.g009
Figure 10. MYC Activation Induces p53 Function, and Loss of p53 Function Is Necessary for MYC to Induce Tumorigenesis in Adult Hepatocytes
(A) Western blot analysis for p53 protein expression after MYC activation for 1 month, 2 months, and in MYC-induced tumors. As a positive
control, we used a lymphoma cell line that overexpresses a mutant p53, kindly provided by Dr. Kevin Smith.
(B) Western blot analysis for p53 protein expression in a normal neonatal liver, in a neonatal liver in which MYC was activated during embryonic
development that was obtained from a 2-d-old mouse, and in MYC-induced neonatal tumors. As a positive control, we used a lymphoma cell line
generated in our lab that overexpresses a mutant p53.
(C) Northern blot analysis for p21 and MDM2 in neonatal and adult liver tumors.
(D) Survival of adult mice after activation of MYC in the presence of the wild type or the loss of one p53 allele.
(E) Loss of heterozygosity analysis of MYC/p53
þ/  tumors by PCR analysis.
DOI: 10.1371/journal.pbio.0020332.g010
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levels, tumor 2264, exhibited a loss in expression of p53 target
genes. In contrast, tumors arising in neonatal mice expressed
p53 protein and exhibited the induction of p53 target genes
(Figure 10B and 10C). We conclude that the adult, but not
neonatal MYC-induced liver tumors require the loss of p53
function for tumorigenesis. Hence, HCCs that arise in adult
versus neonatal hosts appear to occur through genetically
distinct mechanisms.
To directly address if loss of any of p53’s functions
accelerates the ability of MYC to induce HCC in adult mice,
we generated transgenic mice that overexpressed MYC in their
hepatocytes in the absence of one p53 allele. We mated LAP-
tTA/TRE-MYC mice with p53
þ/  mice that were in the FVB/N
background. We activated MYC in mice when they were 6
weeks old and monitored them for morbidity. We found that
even the loss of a single p53 allele was sufﬁcient to reduce the
mean latency of tumor onset in 6-week-old adult mice from 20
weeks to 15 weeks (Figure 10D). We found by PCR that tumors
did not generally inactivate the second allele through deletion
(Figure 10E). Our results extend previous ﬁndings that suggest
that the lack of p53 function cooperates with MYC to induce
HCC (Klocke et al. 2001). We conclude that even a slight
reduction of p53 function greatly facilitates the ability of MYC
to induce tumorigenesis in adult hepatocytes.
Partial Hepatectomy Accelerates MYC-Induced
Tumorigenesis
Our results suggest that the ability of MYC to induce
tumorigenesis in hepatocytes depends on the developmental
context. We recognized that an alternative explanation is that
MYC induces tumorigenesis more readily in hepatocytes that
are already proliferating. Adult hepatocytes are known to
undergo rapid proliferation in response to partial hepatec-
tomy resulting in the complete regeneration of the liver
within 2 weeks of surgical removal (Michalopoulos and
DeFrances 1997; Kountouras et al. 2001). We found that
MYC activation in adult mice that have undergone partial
hepatectomy exhibited a reduced latency of tumor induction
in comparison with adult mice that had not undergone
surgery (mean latency of 14 weeks versus 35 weeks). However,
this latency of tumorigenesis in adult mice after partial
hepatectomy was still up to two magnitudes longer than what
was observed when MYC was activated in embryonic and
neonatal mice (,10 d and 4 weeks, respectively) (Figures 11
and 3A). In addition, tumors in mice that had undergone
partial hepatectomy, unlike tumors arising in neonatal mice,
were multifocal, suggesting that tumorigenesis was occurring
infrequently (Figure 11A versus 4A). Similarly, upon histo-
logical analysis, after MYC was activated for 7 weeks in mice
that had undergone partial hepatectomy, mice exhibited
many individual foci of HCC (Figure 11B and 11C). Finally, in
adult mice after partial hepatectomy, but not in neonatal
mice, areas of the liver that had not undergone neoplastic
conversion clearly exhibited increased cellular hypertrophy,
and hence were unable to undergo mitotic division (unpub-
lished data). We conclude that the ability of MYC to induce
tumorigenesis in adult hepatocytes is accelerated after partial
hepatectomy when adult hepatocytes are proliferating, but
Figure 11. Partial Hepatectomy Accelerates the Ability of MYC to Induce HCC in Adult Mice
(A) Liver from an adult mouse 7 weeks after MYC activation exhibited no gross phenotypic changes (left), whereas the liver from an adult mouse
7 weeks after MYC activation that had undergone partial hepatectomy exhibited a multifocal liver tumor (right).
(B) The histology of the liver from an adult mouse 7 weeks after MYC activation exhibited no evidence of a tumor.
(C) The histology of a liver from an adult mouse after MYC activation that had undergone partial hepatectomy exhibited a multifocal HCC.
(D) Survival after MYC activation in adult mice that have either not undergone surgery (&) or undergone a partial hepatectomy (&). Results are
pooled from two independent experiments with a total of ten mice per group.
DOI: 10.1371/journal.pbio.0020332.g011
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tant in determining when oncogene activation will induce
tumorigenesis than the ability of hepatocytes simply to
proliferate.
Discussion
Developmental Context Influences MYC’s Ability to Induce
Cellular Proliferation
Here we demonstrate that MYC’s ability to induce cellular
growth versus proliferation and tumorigenesis depends on
the differentiative context of a cellular lineage. Our results
have general implications for the mechanisms by which MYC
and other oncogenes induce and are restrained from causing
tumorigenesis.
We found that the initial consequences of MYC over-
expression, as well as its ability to induce tumorigenesis in
murine hepatocytes, depend on the host age. The activation
of MYC during embryonic development and at birth caused
gross liver enlargement and rapid emergence of neoplasia.
This increased liver size resulted from increased cell number
or cellular hyperplasia. In contrast, in adult murine hepato-
cytes, MYC activation induced cell growth, resulting in
cellular hypertrophy and endoreduplication. MYC overex-
pression caused HCC in adult mice less frequently than in
neonates, and only after a prolonged latency. We conclude
that the ability of MYC to induce cellular proliferation and
tumorigenesis appears to be determined by the relative
developmental maturation of a cellular lineage.
We recognized that an alternative explanation for our
results is that only hepatocytes that are actively proliferating
are susceptible to neoplastic transformation upon MYC
induction. We were able to address this possibility directly
by examining the consequences of MYC overexpression in
adult hepatocytes after partial hepatectomy, which resulted
in the immediate induction of adult hepatocyte prolifer-
ation associated with complete liver regeneration within 2
weeks. Adult mice only exhibited a modest increased
susceptibility to MYC-induced tumorigenesis observed when
MYC was induced in embryonic mice. This is despite the fact
that after partial hepatectomy the total number of prolif-
erating hepatocytes would be at least two magnitudes
greater than in a neonatal or embryonic liver, whose total
mass is much smaller. We conclude that developmentally
speciﬁc parameters other than proliferation are more likely
to play a causative role in the differential susceptibility of
embryonic and neonatal hepatocytes to MYC-induced
tumorigenesis.
Several different development-related factors could ac-
count for our observations. The relative ability of MYC to
induce tumorigenesis in developmentally immature hosts
may reﬂect the relative increased abundance of immature
hepatocytes. Homeostatic mechanisms that regulate liver size
and hepatocyte proliferation may permit MYC-induced
proliferative expansion in the developing livers of young
hosts and restrain proliferation in the mature liver of adult
hosts. Differences in rates of tumorigenesis may be related to
telomerase function that monitors the distance from sen-
escence, as recently described (Artandi et al. 2000). An
unlikely possibility is that higher doses of tetracyclines may
impede liver carcinogenesis (NTP 1989). The conditional
model system that we have described should be useful for
addressing these different possible mechanisms.
We conclude that mechanisms that regulate mitotic
division play a critical role in preventing potent oncogenes,
such as MYC, from inducing cancer in adult somatic cells.
MYC activation alone is capable of enforcing DNA replica-
tion, but not cell division (Johnston et al. 1999; Felsher et al.
2000). Mitotic arrest may represent a critical fail-safe
mechanism. If MYC were capable of enforcing mitotic
division as well as cell growth and DNA replication, then
aberrant activation of MYC alone would be sufﬁcient to
induce tumorigenesis. Activation of MYC in immature
hepatocytes, cells already committed to a program of cellular
proliferation, is sufﬁcient to induce tumorigenesis. Activation
of MYC in adult cells must require additional genetic events
that permit mitotic cell division. Notably, our interpretation
of our ﬁndings is supported by similar observations pre-
viously described in keratinocytes (Gandarillas et al. 2000).
We now can offer an explanation for what previously have
been described as discordant results between reports that the
MYC oncogene regulates cellular proliferation and other
reports that MYC regulates cell growth (Mateyak et al. 1997;
Iritani and Eisenman 1999; Johnston et al. 1999; Grandori et
al. 2000; Kim et al. 2000; Trumpp et al. 2001). MYC generally
appears to coordinate cell growth with DNA replication
(Mateyak et al. 1997; Iritani and Eisenman 1999; Johnston et
al. 1999; Grandori et al. 2000; Kim et al. 2000; Trumpp et al.
2001). However, contrary to what has been described, we
show that the ability of MYC to induce cell division may
depend on the developmental context of the cell. In adult
hepatocytes, which normally do not proliferate, MYC activa-
tion can induce cell growth and DNA replication, but not cell
division. In embryonic or neonatal hepatocytes, which are
intrinsically committed to cellular proliferation, MYC activa-
tion induces cell growth, DNA replication, and mitotic
division. Hence, the consequences of MYC activation appear
to depend on the previous commitment of cells in a speciﬁc
developmental state to a cellular program capable only of
growth versus growth and cellular proliferation. It is not clear
whether the hepatocytes that ultimately give rise to the
tumors we observed derive from mitotically arrested diploid
hepatocytes or from polyploid hepatocytes that acquire the
capacity to undergo mitotic division.
MYC Is Restrained from Inducing Proliferation by an Arrest
in Cell Division
Many reports document that p53 functions as a general
surveillance checkpoint that prevents oncogenes from
inducing tumorigenesis (Sherr 1998; Vogelstein et al. 2000;
Wahl and Carr 2001). MYC activation is known to induce
p53 function (Chernova et al. 1998; Zindy et al. 1998;
Schmitt et al. 1999; Felsher et al. 2000; Grandori et al. 2000;
Oster et al. 2002; Pelengaris et al. 2002a, 2002b), which in
turn has been shown to cause apoptosis (Evan et al. 1992;
Zindy et al. 1998; Schmitt et al. 1999; Grandori et al. 2000;
Oster et al. 2002; Pelengaris et al. 2002a, 2002b). In contrast
to these reports, we found that MYC is restrained from
causing cell division in adult hepatocytes, at least in part,
through a p53-dependent mechanism. Our results are
consistent with many reports that demonstrate that p53
regulates checkpoints during DNA replication and during
mitosis (Wahl and Carr 2001).
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precludes MYC from inducing neoplasia in hepatocytes.
Rather, apoptosis is associated with MYC-induced neoplastic
progression. Notably, similar results have been described in
MYC-induced breast cancer and lymphoma (McCormack et
al. 1998; Blyth et al. 2000). There are several possible
explanations for this discordance between our results and
many previous reports. MYC may only induce apoptosis in
some cellular lineages or only in particular differentiative
contexts. In this regard, we have shown that upon inactivating
MYC, tumor cells differentiated, and upon MYC reactivation
in this new differentiative state, cells underwent apoptosis
(Jain et al. 2002). Thus, whether oncogene activation induces
proliferation, growth, arrest, or apoptosis may depend on the
gene expression program of a cell associated with a particular
differentiative state (Felsher 2003).
We found that the ability of MYC overexpression to induce
tumorigenesis in adult hepatocytes often requires the loss of
p53 function. MYC-induced HCC exhibited reduced p53
protein expression and transcriptional activity. The intro-
duction of a single mutant p53 allele greatly accelerated
MYC’s ability to induce tumorigenesis. Hence, in adult
hepatocytes, loss of p53 function appears to be necessary to
permit MYC activation to induce cellular proliferation and
tumorigenesis. Our results here are similar to our previous
observations that normal mouse and human ﬁbroblasts
overexpressing MYC replicate and even endoreduplicate
their DNA, but are unable to undergo mitotic division unless
p53 function has been lost (Felsher et al. 2000).
Specific Developmental Contexts Permit Oncogene-
Induced Tumorigenesis
We may be able to explain why the frequency and spectrum
of neoplasia vary with the host’s age. In general, children are
susceptible to tumors of the hematopoietic system, musculo-
skeletal system, and central nervous system, whereas adults
are susceptible more frequently to tumors derived from
epithelial lineages, such as colon, lung, breast, prostate, and
liver. The ability of oncogenes to induce cancer may be
dependent upon the differentiative context. Frequently,
oncogene activation has been associated with the malignant
conversion of immature cellular compartments (Adams et al.
1985; Spanopoulou et al. 1989; Pelengaris et al. 1999; Blyth et
al. 2000).
We may be able to explain why neonatal versus adult
humans that have become infected with hepatitis B succumb
to HCC with a 100-fold-increased frequency and reduced
latency of tumor onset (Chang et al. 1991, 1997). We infer
that oncogenes in general are more potent in inducing
cancer in hepatocytes of younger hosts because these cells
are committed to a developmental program permissive to
tumorigenesis. Cancers frequently correspond to the malig-
nant expansion of speciﬁc immature differentiative states
within a given cellular lineage (Greaves 1986; Klein and
Klein 1986). It would be advantageous for adult somatic
cells, which are required to be long lived, to acquire
mechanisms that prevent single oncogenes from inducing
inappropriate cellular proliferation and thereby tumori-
genesis. Two such mechanisms have been proposed: Some
oncogenes induce premature senescence (Serrano et al.
1997; Lin et al. 1998; Zhu et al. 1998; Dimri et al. 2000), and
other oncogenes induce apoptosis (Pelengaris et al. 2000).
Here we have provided evidence for a different mechanism:
The aberrant activation of proto-oncogenes, such as MYC, in
the developmental context of adult somatic cells appears to
be inherently prohibited from inducing mitotic division.
The intrinsic inhibition of a proliferative program in
mature somatic cells may be a more parsimonious mechanism
than apoptosis as a means of restraining tumorigenesis
because it would permit otherwise normal fully differentiated
somatic cells to continue to operate despite their acquisition
of an activating mutation in an oncogene. In some cases, it
would be advantageous to arrest cells rather than induce their
apoptosis. Immature cells, which are committed to a program
of proliferative expansion, are inherently more susceptible to
oncogene-induced autonomous proliferation and tumori-
genesis. In immature cells, apoptosis may be the only
mechanism that could prevent tumorigenesis. Thus, the
differentiative state and epigenetic program of a cell
inﬂuences whether an oncogene induces cellular senescence,
mitotic arrest, or apoptosis.
Generally, oncogenes may cause tumorigenesis most
readily in developmental contexts that provide a gene
expression program permissive to tumorigenesis (Jain et al.
2002; Felsher 2003). Pathologic conditions that trigger the
expansion of immature cells—tissue injury and regenera-
tion, infection, and autoimmune processes—may be asso-
ciated with cancer because they change the cellular state,
now permitting a single oncogene, such as MYC, to initiate
tumorigenesis. In this regard, we found that MYC accel-
erated tumorigenesis in adult hosts that had undergone
partial hepatectomy and were undergoing liver regenera-
tion—a state that induces robust cellular proliferation.
However, tumorigenesis was not accelerated to the same
degree as observed when MYC was activated in embryonic or
neonatal hosts. Therefore, inducing the capacity of a cell to
proliferate alone is unlikely to be sufﬁcient to confer
susceptibility to tumorigenesis. It has long been appreciated
that conferring the ability of a cell to proliferate is not
sufﬁcient to induce tumorigenesis. Other developmentally
speciﬁc parameters may play a more critical role in deﬁning
when oncogene activation results in tumorigenesis. The
model system we have developed should prove useful in
deﬁning how particular developmental contexts and patho-
logic states contribute to tumorigenesis.
Materials and Methods
Transgenic mice. The TRE-MYC transgenic line generated for
these experiments was described previously (Felsher and Bishop
1999b). The LT-tTA transgenic line was kindly provided by H.
Bujard (Kistner et al. 1996). The p53
þ/  mice were generously pro-
vided by A. Bradley. Mice were mated and screened by PCR. MYC
expression was activated by removing doxycycline treatment (100 lg/
ml) from the drinking water of mice transgenic for both TRE-MYC
and LAP-tTA.
Tumorigenicity assays. MYC was activated in the liver by removing
doxycycline treatment from the water. MYC was activated during
embryonic development by removing doxycycline treatment from
the mating cage before conception. MYC was activated at birth by
removing doxycycline from the mating cage immediately after the
birth of the litter. Mice were monitored daily and were sacriﬁced
when moribund. During necropsy, liver tissues were saved by
ﬁxation in 10% buffered formalin or by being snap frozen in liquid
nitrogen. For transplantation, liver tumor specimens were sliced
into small pieces, incubated ﬁrst in calcium-free Hank’s Buffered
Saline Solution (HBSS) on a stirring plate at 37 8C for 20 min, then
washed and resuspended in 13 digestion buffer with 1.5 mg/ml
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additional 40 min. The solution was then ﬁltered through a 100-lm
ﬁlter, washed, and resuspended in PBS twice. After the ﬁrst wash, the
solution was resuspended in 10 ml of PBS. After the second ﬁltering
and wash, the solution was resuspended in 500 ll of PBS. A quantity
of 10
6 cells was injected subcutaneously into scid mice (250 ll per
injection) using a 1-ml syringe and 27-gauge needle. Mice showed
signs of tumorigenesis within 2–3 weeks of inoculation. Mice were
sacriﬁced when tumors reached 2 cm in size. To prepare 53
digestion buffer, 1.12 g of KCl, 37.94 g of NaCl, 0.69 g of
NaH2PO4*H2O, and 9.9 g of dextrose monohydrate were dissolved
in 1 liter of H2O.
Partial hepatectomy. The median and left lateral lobes comprise
about 70% of the liver and their removal is recognized classically as
a partial hepatectomy. We performed a one-third partial hepatec-
tomy, removing only the median lobe of the liver. Mice were
anesthetized with 16 mg/kg ketamine/xylazine. An incision was made
through the midline ventral abdominal skin and abdominal muscles,
extending from just above the xiphoid cartilage to about halfway
towards the base of the tail. A small bolster was placed under the
thorax, causing the liver to fall forwards away from the diaphragm.
The liver was pushed out and the suspensory ligaments were cut
with blunt-end scissors. The median lobe was raised and a ligature
was tied around it with the blood vessels at the base. The liver lobe
was removed by cutting close to the ligature with sharp scissors. The
bolster was removed and the muscle and skin incisions were closed.
The mice were monitored hourly for pain and dehydration after the
procedure.
Histology. Liver tissues were ﬁxed in 10% buffered formalin for
24 h and then transferred to 70% ethanol until embedding in
parafﬁn. Tissue sections 4 lm thick were cut from parafﬁn-
embedded blocks and placed on glass slides. Hematoxylin and eosin
(H&E) staining was performed using standard procedures. The
Stanford Histology Core laboratory prepared parafﬁn sections and
performed H&E staining. We measured Ki67 expression by
immunoﬂuorescence using a mouse anti-human Ki67 monoclonal
antibody (BD Biosciences, Palo Alto, California, United States). We
used the Vector M.O.M. Basic Kit (Vector Laboratories, Burlingame,
California, United States). Sections were deparafﬁnized with xylene
and rehydrated through graded alcohol washes, followed by antigen
retrieval in a microwave for 15 min in Vector Antigen Unmasking
solution (H-3300). The slides were then incubated in 100 mM
glycine for 2 3 8 min to reduce ﬂuorescent background. Slides were
blocked by incubation in avidin for 10 min followed by biotin for 10
min using the Dako biotin blocking system (DAKO Corporation,
Carpinteria, California, United States) and subsequently incubated
for 1 h in M.O.M. IgG-blocking reagent diluted 1:4 in PBS. Slides
were then incubated for 1 h in mouse anti-human Ki67 monoclonal
antibody diluted 1:100 in M.O.M. diluent. Slides were washed in
TBST for 3 3 5 min to reduce background and were then treated
with M.O.M. biotin-labeled anti-mouse IgG, diluted 1:250 in M.O.M.
diluent. Following another 3 3 5 min of TBST washes, slides were
incubated for exactly 45 min in Cy3-conjugated streptavidin diluted
1:800 in PBS (Amersham Biosciences, Piscataway, New Jersey, United
States) in the dark. To visualize nuclei, slides were counterstained
with 0.2 lg/ml DAPI. Ki67-positive cells were visualized by
ﬂuorescence microscopy.
Western blot analysis. Western analysis was performed using
conventional techniques. Liver tissues were disrupted and protein
was isolated using a pestle and tube homogenizer in NP-40 lysis
buffer. Equal protein was loaded in each lane, as quantitated by the
Bicinchoninic Acid (BCA) Protein Assay (Pierce, Rockford, Illinois,
United States). Proteins were electrophoresed on 10% Tris-HCl
polyacrylamide gels at 100 V for 60 min and transferred on PVDF
membranes at 100 V for 60 min. The membrane was blocked in 5%
nonfat dry milk solution in TBS at 4 8C overnight. MYC protein
expression was detected using the C-19 rabbit polyclonal antibody
that recognizes mouse and human MYC (Santa Cruz Biotechnology,
Santa Cruz, California, United States). p53 protein expression was
detected using the NCL-p53-CM5p rabbit polyclonal antibody
(Vector Laboratories). As a positive control, we used a hematopoietic
tumor previously shown to overexpress p53 that was generously
provided by Dr. Kevin Smith.
Cell and nucleus size measurements. Images of H&E-stained liver
sections were made with a Nikon Eclipse E800 microscope utilizing a
Spot RT Slider digital camera (Diagnostic Instruments, Sterling
Heights, Michigan, United States) and Spot Advanced Software
(version 3.2.4, Diagnostic Instruments). To estimate cellular and
nuclear volume, the radii of at least ﬁve hepatocytes per ﬁeld were
measured in at least three ﬁelds.
Hepatocyte isolation. Hepatocytes were collected by a two-step in
situ perfusion technique (Seglen 1976; Bumgardner et al. 1990). First,
the inferior vena cava was cannulated and the liver perfused with
calcium-free EGTA buffer followed by calcium-containing collage-
nase buffer (Invitrogen, Carlsbad, California, United States). After the
perfusion, the liver was excised and mechanically disrupted in
Williams’ E medium (Sigma-Aldrich, St. Louis, Missouri, United
States). The resulting slurry was ﬁltered through a 40-lm ﬁlter, and
viable hepatocytes were isolated by Percoll gradient centrifugation.
The pelleted hepatocytes were washed serially with Williams’ E
medium and counted prior to further analyses.
Cell size measurements by FACS analysis. Cell size was determined
by FACS forward versus light scatter of isolated hepatocytes utilizing
a Becton Dickinson FACSCaliber (BD Biosciences). Data were
analyzed using Cellquest v3.3 Software (BD Biosciences).
DNA content. Nuclei were prepared for staining by touching a cut
piece of liver to superfrost slides. The smears were then air dried,
ﬁxed in formalin for 5 min, and stored in 70% ethanol. The nuclei
were stained for DNA content analysis according to the Feulgen
technique (Oppedal et al. 1988).
Apoptosis assay. Apoptosis was detected using terminal deoxy-
ribonucleotidyl transferase-mediated dUTP nick end labeling (TU-
NEL) staining, using the In Situ Death Detection Kit (Boehringer
Mannheim, Indianapolis, Indiana, United States). In order to visualize
the nuclei, cells were counterstained with DAPI (0.2 lg/ml). TUNEL-
positive cells were visualized by ﬂuorescence microscopy.
Northern blot analysis. Northern blotting and probing were
performed using standard methods. RNA samples were isolated
according to the Trizol product manual speciﬁcations using a Kontes
1-ml glass tissue homogenizer. A formaldehyde, 1% agarose gel was
used to run the Northerns, and transferring was done overnight in
203 SSC. Blots were washed in 23 SSC, cross-linked twice in a
Stratalinker UV source, and pre-hybed and hybridized using the
UltraHyb (Ambion, Austin, Texas, United States) product speciﬁca-
tions. cDNAs corresponding to p21, MDM2, and glyceraldehye-3-
phosphate dehydrogenase (GAPDH) were used as probes (Macleod et
al. 1995; el-Deiry 1998). The probes were generated through random
priming reactions. Kodak BioMax MS ﬁlm was used to expose the
blots.
Loss of p53 heterozygosity analysis by PCR. To evaluate loss of
heterozygosity of liver tumors derived from mice heterozygous for
p53 deletion, PCR analysis was performed as previously described
(Timme and Thompson 1994).
RNA isolation and quantiﬁcation. Total cellular RNA was isolated
from snap-frozen liver tissue using the Invitrogen Micro-to-Midi
Total RNA Puriﬁcation System according to the manufacturer’s
instructions. The amount of total RNA isolated from tissues was
quantiﬁed using spectrophotometric OD260 measurements. The
quality of RNA was measured on a formaldehyde, 1% agarose gel.
Real-time PCR. The RNA of human c-MYC and rodent GAPDH
were measured by real-time quantitative RT-PCR using the 59
nuclease technology on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems, Foster City, California, United States).
The probe sequences for human c-MYC were forward primer
59-CCCCTGGTGCTCCATGAG-39 and reverse primer
59-GCCTGCCTCTTTCCACAGA-39. The human c-MYC probe,
59-TCCTCCTCAGAGTCGC-39, was labeled with FAM dye-MGB. A
VIC TaqMan rodent GAPDH control reagents kit (Applied Biosys-
tems) was used to measure mouse GAPDH. The RNA was reverse
transcribed using the High-Capacity cDNA Archive Kit (Applied
Biosystems) according to the manufacturer’s protocol with a minor
modiﬁcation, the addition of RNase inhibitor (Applied Biosystems) at
a ﬁnal concentration of 1 U/ll. Samples were incubated at 25 8C for
10 min and 37 8C for 180 min. PCR reactions were prepared in a ﬁnal
volume of 20 ll, with ﬁnal concentrations of 13 TaqMan Universal
PCR Master Mix (Applied Biosystems) and cDNA derived from 20 ng
of input RNA as determined by spectrophotometric OD260 measure-
ments. Thermal cycling conditions comprised an initial UNG
incubation at 50 8C for 2 min, AmpliTaqGold DNA polymerase
activation at 95 8C for 10 min, 40 cycles of denaturation at 95 8C for
15 s, and annealing and extension at 60 8C for 1 min. Each mea-
surement was performed in triplicate and the threshold cycle (Ct), the
fractional cycle number at which the amount of ampliﬁed target
reached a ﬁxed threshold, was determined. For calibration and
generation of standard curves, we used cDNA prepared from
Universal Human Reference RNA (Stratagene, La Jolla, California,
United States) and cDNA prepared from Universal Mouse Reference
RNA (Stratagene). Universal Human Reference RNA was used for
human c-MYC and Universal Mouse Reference RNA was used for
rodent GAPDH.
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Accession Numbers
Swiss-Prot accession numbers (http://us.expasy.org/sprot/) for the loci
discussed in this paper are the following: Cdkn1a (mouse), P39689;
Mdm2 (mouse), P23804; Myc (human), P01106; Myc (mouse), P01108;
and Tp53 (mouse), P02340.
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